Keyword: Takeda

The fund sets Frazier up to place another set of bets spanning from company creation through public investments.

Emendo has worked to expand the list of diseases amenable to treatment with gene editing, resulting in hematology and ophthalmology programs. 

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Takeda announced a new preclinical tie-up.

Fierce 15 winner Turnstone Biologics has penned a near $1 billion biobucks deal with biotech’s best friend, Takeda.

The duo kept details close to the vest but said Cerevance could net more than $170 million in milestones for each target Takeda moves forward.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

The deal grants Takeda rights to up to four programs, including natural killer cell therapies aimed at CD19 and BCMA.

As Japanese pharma Takeda keeps divesting assets, its new big biotech buy Shire keeps divesting research executives.

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.